Minimally invasive evacuation of spontaneous supratentorial intracerebral hemorrhage by transcranial neuroendoscopic approach

Qiang Cai1
Qiao Guo1
Zhiyang Li1
Wenju Li1
Wenfei Zhang1
Baowei Ji1
Zhibiao Chen1
Jun Liu2

1Department of Neurosurgery, Renmin Hospital of Wuhan University, Hubei Province, People’s Republic of China; 2Department of Emergency, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, People’s Republic of China

Objective: Spontaneous supratentorial intracerebral hemorrhage (SSICH) is one of the deadliest diseases, and neuroendoscopic surgery (NE) is a minimally invasive and promising treatment that might improve the functional recovery of patients. This study analyzed patient’s experience with this treatment in terms of safety, efficacy, and surgical technique.

Patients and methods: Forty-two patients with SSICHS treated by transcranial neuroendoscopic approach were retrospectively reviewed from June 2016 to July 2018 in our department. Patients were classified into four groups according to the main location of the hematoma on CT scans: Group A (basal ganglia hemorrhage), Group B (subcortical hemorrhage), Group C (thalamic hemorrhage), and Group D (intraventricular hemorrhage [IVH]). The clinical data were collected, and the outcomes were analyzed.

Results: All procedures were successfully completed, and no patient died in the perioperative period. The average hematoma evacuation rate was 90.1%, and the highest hematoma evacuation rate was achieved in Group B which was 92.7%. No severe complications occurred, and the average GCS score improvement was 4.0 at discharge.

Conclusion: These data suggest that evacuation hemorrhage by neuroendoscopy might be an effective and safe approach for SSICH. For better efficiency of this treatment, some details needed to be emphasized, such as setting up a good working channel, using of suction and bipolar forceps accurately.

Keywords: supratentorial intracerebral hemorrhage, transcranial neuroendoscopic approach, minimally invasive surgery

Introduction

Spontaneous supratentorial intracerebral hemorrhage (SSICH) is the deadliest disease and has high morbidity rate, high mortality rate, high disability rate, and high economic burden. The 30-day mortality is approximately 40%, and up to 75% of the long-term survivors suffer significant disability. Unfortunately, the use of the traditional craniotomy for SSICH remains a matter of controversy and has not been demonstrated to significantly improve outcome compared with medical management.

Recent reports have demonstrated that neuroendoscopic surgery (NE) is a minimally invasive treatment that is an attractive alternative and a promising procedure that may improve the rate of good functional recovery from intracerebral hemorrhage (ICH). However, according to the American Heart Association/American Stroke Association Guidelines, supporting evidence for this method from controlled trials is still lacking. Therefore, we present our series of patients with SSICH who underwent neuroendoscopic hematoma evacuations and discuss the safety, efficacy, and surgical technique of this approach.
Patients and methods
Surgical indications and patient selection
Forty-two patients with SSICH treated by the transcranial neuroendoscopic approach were retrospectively reviewed from June 2016 to July 2018 in our department. The clinical data were collected, and the outcomes (including the average surgery time, hematoma evacuation rate, perioperative mortality, and Glasgow Coma Scale [GCS] improvement) and complications (including rebleeding, pneumonia, and intracranial infection) were analyzed. Patients were classified into four groups according to the main location of the hematoma on CT scans: Group A (basal ganglia hemorrhage), Group B (subcortical hemorrhage), Group C (thalamic hemorrhage), and Group D (intraventricular hemorrhage [IVH]) (Table 1). The intracerebral hematoma volumes were analyzed with 3D Slicer software (http://www.slicer.org). All patients underwent a CT scan before the operation, a post-operation CT scan within 24 hours after the surgery, and a follow-up CT or MRI scan 3 days to 1 month after the operation. The hematoma evacuation rate was calculated as follows: ([preoperative hematoma volume – postoperative hematoma volume]/preoperative hematoma volume)×100% (Figure 1A and B). After surgery, the patients were managed in the intensive care unit, the blood pressure was controlled, and the consumption of excessive fluid was not allowed.

The inclusion criteria for this study were the following: 1) diagnosis of acute SICH, 2) hematoma volume greater than 30 mL for a putaminal ICH, 3) hematoma volume greater than 20 mL for a thalamic ICH, 4) IVH with acute hydrocephalus, 5) subcortical hemorrhage greater than 30 mL with a significant mass effect (midline shift greater than 5 mm), 6) a GCS score ≥5, and 7) stable vital signs. The exclusion criteria were the following: 1) the ICH was caused by secondary factors (eg, arteriovenous malformation, aneurysm, tumor stroke, or head injury); 2) serious visceral disease or clotting disorders (ie, a prothrombin time >12.2 seconds, a partial thromboplastin time >35.5 seconds, or a platelet count <100×10^9/mL); 3) a GCS of <5; and 4) multiple intracranial hemorrhages.

Neuroendoscopic surgical management
This study was approved by the ethics committee of Renmin Hospital of Wuhan University. All patients or their family provided written informed consent, and this procedure was conducted in accordance with the Declaration of Helsinki.

All surgeries were performed under general anesthesia with the patients in the supine position. The surgical approaches were chosen according to the locations of the hematomas. Typically, a linear scalp incision (4–5 cm) was made, and then, a small bone flap (~2.5 cm) was created. After tenting the dura, it was opened in a cruciate fashion. A 1.5 cm cortical incision was made, and a transparent plastic sheath was inserted into the hematoma cavity. A 0° rigid endoscopy (Karl Storz, Germany) was introduced into the space that was created by the hematoma, and suction was used to keep surgical field clear. Usually, most of the clot and blood gushed out due to high pressure and were removed under direct vision by endoscopy. During the operation, obvious bleeding was stopped using a bipolar coagulator with a low output power.

After evacuation of the hematoma, a soft catheter was laid inside the hematoma cavity to drain any residual liquid hematoma, the bone flap was recovered, and the skin incision was closed (Figure 2A–F).

Results
The 42 patients in this study included 28 men and 14 women with a median age of 59.7 years (range 41–79 years). Among these patients, there were 22 cases in Group A (52.3%), 10 cases in Group B (23.8%), six cases in Group C (14.3%), and four cases in Group D (9.5%) (Table 1). In Group A, we usually selected the “temporal” approach, and the post-operation CT scans indicated that the hematomas were nearly completely evacuated by the neuroendoscopy. The follow-up CT scans revealed that these patients recovered well based on the images (Figure 3A–E). In Group B, the corridor shortest distance to the hematoma was used and also the hematoma was evacuated satisfactorily (Figure 4A–E). In Group C, a midline approach in which the ipsilateral Kocher point served as the entry point and the follow-up CT scans indicated that no further damage to the thalamus was caused by neuroendoscopy (Figure 5A–E). In Group D, also the ipsilateral Kocher point was selected and the post-operation CT scans showed well (Figure 6A–E). The preoperative hematoma volume was 49.5 mL (24.3–122.5 mL), and the average hematoma evacuation rate was 90.1%. The highest hematoma evacuation rate was achieved in Group B (92.7%), the second highest in Group A (90.7%), the third highest in Group D (87.9%), and the lowest in Group C (84.6%).

All procedures were successfully completed, and the average surgery time ranged from 47.5 to 85.6 minutes with a mean length of 63.1 minutes. The median GCS scores were 7.3 before surgery and 11.3 at discharge; thus, the average GCS score improvement was 4.0.

No patients died within 3 days of surgery, and the surgery-related mortality was 0%. However, three patients were discharged at GCS 3 and died in their home for no
neuropsychiatric disease and treatment 2019:15
submit your manuscript | www.dovepress.com

cai et al
improvement after surgery and their family decided to give up further treatment. Thus, the total mortality rate was 7.1%. One patient experienced rebleeding due to malignant hypertension 4 days after the surgery, and the rebleeding rate was 2.4%. The hematoma of this rebleeding patient was 25 mL, and conservative treatment was administered by fibrinolysis agent (containing 20,000 U–40,000 U urokinase/2–3 mL saline solution) for 3 days. The patient’s

Table 1  Demographic and clinical characteristics of the 42 patients with SSICH

<table>
<thead>
<tr>
<th>Case no</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Preop GCS score</th>
<th>Postop GCS score</th>
<th>Preop ICH volume (cm³)</th>
<th>Postop ICH volume (cm³)</th>
<th>ICH location</th>
<th>Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>75</td>
<td>5</td>
<td>6</td>
<td>51.2</td>
<td>14.7</td>
<td>Thalamus/left BG</td>
<td>C</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>71</td>
<td>5</td>
<td>6</td>
<td>69.6</td>
<td>6.2</td>
<td>Thalamus/right BG</td>
<td>C</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>50</td>
<td>7</td>
<td>15</td>
<td>53.5</td>
<td>1.5</td>
<td>Left BG/ventricles</td>
<td>A</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>71</td>
<td>5</td>
<td>14</td>
<td>50.3</td>
<td>9.8</td>
<td>Left BG/ventricles</td>
<td>A</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>54</td>
<td>11</td>
<td>11</td>
<td>31.7</td>
<td>1.8</td>
<td>Left frontal lobe/BG</td>
<td>B</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>52</td>
<td>8</td>
<td>3</td>
<td>45.2</td>
<td>1.8</td>
<td>Right BG</td>
<td>A</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>56</td>
<td>5</td>
<td>15</td>
<td>50.4</td>
<td>1.5</td>
<td>Left frontal lobe/BG</td>
<td>B</td>
</tr>
</tbody>
</table>
| 8       | F   | 48          | 9               | 15              | 36.3                   | 4.1                    | Right parietal lobe/ventricles | B       
| 9       | F   | 67          | 11              | 15              | 41.9                   | 1.2                    | Right BG/ventricles    | A      |
| 10      | M   | 63          | 5               | 14              | 122.5                  | 5.3                    | Left BG/ventricles     | A      |
| 11      | M   | 45          | 7               | 3               | 70.2                   | 14.6                   | Left BG                | A      |
| 12      | M   | 79          | 6               | 7               | 48.7                   | 1.2                    | Right BG/ventricles    | A      |
| 13      | F   | 64          | 10              | 15              | 51.6                   | 1.8                    | Right temporal/parietal lobe | B       
| 14      | M   | 51          | 9               | 12              | 46.8                   | 7.3                    | Left BG                | A      |
| 15      | M   | 56          | 8               | 4               | 42.3                   | 3.4                    | Left BG                | A      |
| 16      | F   | 65          | 10              | 15              | 35.1                   | 4.8                    | Right frontal lobe/ventricles | B       
| 17      | M   | 41          | 8               | 15              | 32.3                   | 3.1                    | Ventrices              | D      |
| 18      | M   | 57          | 9               | 14              | 35.6                   | 5.4                    | Right thalamus         | C      |
| 19      | M   | 47          | 9               | 15              | 37.7                   | 6.3                    | Ventrices              | D      |
| 20      | M   | 48          | 9               | 15              | 69.4                   | 7.2                    | Right BG               | A      |
| 21      | M   | 53          | 12              | 15              | 25.4                   | 5.1                    | Left thalamus/ventricles | C       
| 22      | M   | 41          | 5               | 15              | 45.8                   | 4.1                    | Right BG               | A      |
| 23      | M   | 77          | 5               | 5               | 88.3                   | 8.9                    | Left BG/ventricles     | A      |
| 24      | F   | 47          | 9               | 14              | 36.2                   | 4.3                    | Left BG                | A      |
| 25      | F   | 63          | 5               | 5               | 53.7                   | 5.2                    | Right BG/ventricles    | A      |
| 26      | M   | 67          | 5               | 5               | 75.6                   | 8.4                    | Right BG/ventricles    | A      |
| 27      | M   | 73          | 12              | 15              | 32.5                   | 3.2                    | Left parietal lobe     | B      |
| 28      | M   | 64          | 7               | 15              | 33.1                   | 4.8                    | Right BG               | A      |
| 29      | F   | 68          | 9               | 13              | 27.7                   | 3.4                    | Ventrices              | D      |
| 30      | M   | 58          | 5               | 12              | 51.5                   | 4.6                    | Right BG               | A      |
| 31      | M   | 51          | 5               | 11              | 63.3                   | 4.2                    | Left temporal lobe/BG  | B      |
| 32      | M   | 69          | 6               | 11              | 56.8                   | 5.6                    | Left thalamus/BG       | C      |
| 33      | F   | 43          | 7               | 13              | 38.4                   | 3.9                    | Right BG               | A      |
| 34      | M   | 77          | 7               | 12              | 76.7                   | 5.8                    | Right BG/ventricles    | A      |
| 35      | F   | 55          | 5               | 9               | 68.2                   | 5.3                    | Left BG/ventricles     | A      |
| 36      | M   | 67          | 8               | 14              | 47.6                   | 3.1                    | Left BG/ventricles     | A      |
| 37      | F   | 63          | 5               | 8               | 34.7                   | 3.3                    | Right frontal lobe/ventricles | B       
| 38      | M   | 53          | 8               | 12              | 26.4                   | 2.2                    | Ventrices/left thalamus | D       
| 39      | F   | 74          | 5               | 7               | 75.2                   | 7.8                    | Left BG/ventricles     | A      |
| 40      | M   | 74          | 5               | 3               | 24.3                   | 3.5                    | Right thalamus/ventricles | C       
| 41      | M   | 57          | 9               | 15              | 42.8                   | 2.1                    | Left parietal lobe     | B      |

Notes: Group A (basal ganglia hemorrhage), Group B (subcortical hemorrhage), Group C (thalamic hemorrhage), and Group D (intraventricular hemorrhage [IVH]).
Abbreviations: BG, basal ganglia; F, female; GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage; M, male; preop, preoperative; postop, postoperative; SSICH, spontaneous supratentorial intracerebral hemorrhage.
GCS score improved gradually after draining and reached 14 at discharge. Pneumonia happened in three cases, and no patient died from this complication. There were no cases of intracranial infection.

Discussion

Although spontaneous ICHs account for only 15% of all strokes, this condition is the most dangerous and disabling form of stroke. The high mortality rate of SSICH patients has been found to be significantly associated with the hematoma volume, treatment method, and location of the hematoma. Rost et al concluded that ICH volumes are frequently used in clinical decision-making and categorized the volumes as, 30 mL, 30–60 mL, and >60 mL. In Bhaskar’s study, the mortality rate at 3 months was found to be directly proportional to hematoma volume ($P=0.039$); the mortality rates reported in this study were 56.4% among patients with hematoma volumes in the range of 31–60 mL, 81% for volumes in the range of 61–90 mL, and 100% for volumes >90 mL.

The choice of treatment for SSICH is difficult, but medical treatment is usually recommended for patients with small cerebral hemorrhages. However, the best therapeutic option for those with medium-to-large-sized SSICHs remains controversial. Juvela et al found that there were no significant differences in mortality or morbidity rates between patients who were treated surgically and those who were treated conservatively; however, the mortality rate was significantly lower in the surgical group among patients with GCS scores between 7 and 10.

Moreover, the Surgical Trial in Intracerebral Hemorrhage (STICH) studied 1,033 patients with SSICH and reported that there was no overall benefit of surgical intervention compared with nonsurgical management. However, in

![Figure 1](https://www.dovepress.com/)

Notes: (A) The preoperative hematoma volume was 30.9 mL. (B) The postoperative hematoma volume was 0.3 mL. The hematoma evacuation rate was 99.0%.

![Figure 2](https://www.dovepress.com/)

Notes: (A) After opening the dura matter, the intracerebral pressure was high. (B) A transparent sheath was inserted into the hematoma cavity, and hematomas was evacuated by neuroendoscopy. (C) A catheter was inserted into the hematoma cavity to drain any residual liquid hematoma after the hematoma was removed. (D) The bone flap was approximately 2.5 cm. (E) The small bone flap was recovered and fixed. (F) The skin incision was short, only approximately 4 cm.
Mukesh’s study,\textsuperscript{13} the mortality rate at 3 months was significantly lower in the surgical group (61.8%) than in the conservative group (85.2%; $P=0.043$), and the mortality rate was significantly higher (80.5%) among patients with GCS scores of 4–8 compared with those with GCS scores of 9–14 (55%) among both the surgical and conservative treatment groups ($P=0.037$). Furthermore, among patients with GCS scores of 4–8, the mortality rate of the surgical group (65.2%) was found to be significantly lower than that of the conservative therapy group (100%; $P=0.005$). Despite the findings of multiple prior surgical trials, the current conservative treatment is insufficient, especially for patients with hemorrhages occupying large spaces and secondary deterioration.\textsuperscript{16} Thus, Gregson and Mendelow concluded that there is no convincing evidence of the benefit of any medical treatment, and the role of surgery remains controversial.\textsuperscript{17} Furthermore, the efficacy of any medical or surgical treatment has yet to be proven in a large randomized trial.

The main drawback of traditional surgery is the invasive procedure, which causes too much damage and fails to protect the still-functional brain tissue. An analysis of more than 45,000 patients revealed that the in-hospital mortality rate for this method is 27.2%, and the complication rate (eg, pulmonary, renal, and thromboembolic complications) is 41.2%.\textsuperscript{18} Compared with conventional craniotomy, endoscopic surgery offers a minimally invasive treatment option with a more favorable safety profile than traditional approaches that do not compromise efficacy. Accumulating evidence indicates that the endoscopic approach might provide minimal invasiveness, maximum efficiency in clot removal, and maximum patient safety.\textsuperscript{19,20} Prasad et al\textsuperscript{21} reported that endoscopic evacuation decreased the risk of death and dependence in patients with hematoma volumes greater than 50 mL. Auer et al\textsuperscript{22} reported lower mortality (3%) and lower morbidity (3%) in an endoscopic group, and Cho et al\textsuperscript{23} reported that the mortality rate was decreased to 0% via the use of the endoscopic approach. In terms of complications, the study from Nagasaka indicated that the endoscopic approach was associated with a minimal rebleeding rate (0%–3.3%) compared with the traditional craniotomy approach (5%–10%).\textsuperscript{24} In the treatment of basal ganglia hemorrhages, Zhang et al\textsuperscript{8} reported a lower rebleeding rate in an endoscopic group than in a control group (4.76% versus 10%), but this result was not statistically significant ($P=0.50$).

In recent decades, some studies have demonstrated high evacuation rates following the treatment of SSICHs via the endoscopic approach. Zhang et al\textsuperscript{8} reported that the hematoma evacuation rate in an endoscopic group was higher than that in a traditional craniotomy group ($P<0.05$). Cho et al\textsuperscript{23} successfully evacuated 92% of a 120 mL hematoma using...
endoscopic surgery, and Nishihara et al achieved almost complete evacuation (86%–100%) of a hematoma greater than 40 mL without complications.

Additionally, several series have reported lower rates of rebleeding, morbidity, and mortality, following endoscopic surgery compared with traditional craniotomy. The main reasons for these findings are reduced adjacent tissue injury, less blood loss, and reduced operation times. Truly minimally invasive surgery involves not only a minimal wound size but also minimal brain tissue trauma during surgery. In our study, we achieved a similar result, and the average hematoma evacuate rate was 90.1%, which confirms the effectiveness of the neuroendoscopic technique. In conclusion, the application of the neuroendoscopic approach might be an effective and safe approach for SSICH.

To achieve these advantages, some of the surgical techniques of the endoscopic approach require an emphasis on the protection of the surrounding brain regions to achieve better prognoses. Setting up a good working channel is the first and important step in NE, and many working channels, such as transparent sheaths or other handmade sheaths, have been developed and reported in the literature. These techniques allow for the dynamic, multangled evacuation of the hematoma, clot cavity control, and hemostasis without harming the brain parenchyma.

**Conclusion**

The key advantage of the minimally invasive approach is the drastically reduced manipulation of viable brain tissue; thus, the use of suction and a bipolar coagulator are also important in the neuroendoscopic approach for the treatment of SSICH. Similar to the report of Wang et al, in our practice, we used suction only to evacuate the hematoma, and a thin hematoma over the surrounding brain tissue could be left intact. The power applied with the bipolar forceps was the minimum possible that still achieved the coagulation of the bleeding vessel, and hemostatic agents were used instead of coagulation if there was merely minor oozing.

**Abbreviations**

GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage; NE, neuroendoscopic surgery; SSICH, Spontaneous Supratentorial Intracerebral Hemorrhage.

**Acknowledgment**

This work was supported by National Natural Science Foundation of China (81671306) and the Foundation of China Scholarship Council.
Disclosure

The authors report no conflicts of interest in this work.

References


